# Question 39

**Type:** Mutation Subtype Analysis

**Question:** "What are the survival differences between EGFR-mutated, EGFR-amplified, and EGFR wild-type lung adenocarcinoma patients?"

**Answer:**

I'll help you analyze survival differences between EGFR-mutated, EGFR-amplified, and EGFR wild-type lung adenocarcinoma patients. Let me start by finding the appropriate lung adenocarcinoma study.



Calling `resolve_and_route` with args:
```json
{
  "targetPage": "results",
  "studyKeywords": [
    "lung",
    "adenocarcinoma",
    "TCGA"
  ]
}
```



Result from `resolve_and_route`:
```json
{"success":true,"message":"Found 4 matching studies. Review the user's original query to determine if it clearly matches one study. If yes, use that study's metadata to call navigate_to_resultsview. If ambiguous, ask the user to choose.","data":{"recommendedTool":"navigate_to_resultsview","needsStudySelection":true,"totalCount":4,"resolvedStudyIds":["luad_tcga","luad_tcga_gdc","luad_tcga_pan_can_atlas_2018","luad_tcga_pub"],"studiesWithMetadata":[{"studyId":"luad_tcga","name":"Lung Adenocarcinoma (TCGA, Firehose Legacy)","sampleCount":1166,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=luad_tcga","metadata":{"clinicalAttributeIds":["AGE","AJCC_CLINICAL_TUMOR_STAGE","AJCC_METASTASIS_CLINICAL_CM","AJCC_METASTASIS_PATHOLOGIC_PM","AJCC_NODES_CLINICAL_CN","AJCC_NODES_CLINICAL_CT","AJCC_NODES_PATHOLOGIC_PN","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","AJCC_TUMOR_PATHOLOGIC_PT","ALK_ANALYSIS_TYPE","ALK_TRANSLOCATION_STATUS","ALK_TRANSLOCATION_VARIANT","CANCER_TYPE","CANCER_TYPE_DETAILED","CARBON_MONOXIDE_DIFFUSION_DLCO","DAYS_TO_COLLECTION","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DAYS_TO_PATIENT_PROGRESSION_FREE","DAYS_TO_SPECIMEN_COLLECTION","DAYS_TO_TUMOR_PROGRESSION","DFS_MONTHS","DFS_STATUS","DISEASE_CODE","ECOG_SCORE","ETHNICITY","EXTRANODAL_INVOLVEMENT","FEV1_FVC_RATIO_POSTBRONCHOLIATOR","FEV1_FVC_RATIO_PREBRONCHOLIATOR","FEV1_PERCENT_REF_POSTBRONCHOLIATOR","FEV1_PERCENT_REF_PREBRONCHOLIATOR","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","HISTOLOGICAL_DIAGNOSIS","HISTORY_IMMUNOLOGICAL_DISEASE","HISTORY_IMMUNOLOGICAL_DISEASE_OTHER","HISTORY_NEOADJUVANT_TRTYN","HISTORY_OTHER_MALIGNANCY","HISTORY_RELEVANT_INFECTIOUS_DX","HIV_STATUS","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","INITIAL_PATHOLOGIC_DX_YEAR","IS_FFPE","KARNOFSKY_PERFORMANCE_SCORE","KRAS_GENE_ANALYSIS_INDICATOR","KRAS_MUTATION","KRAS_MUTATION_IDENTIFIED_TYPE","LATERALITY","LOCATION_LUNG_PARENCHYMA","LONGEST_DIMENSION","METHOD_OF_INITIAL_SAMPLE_PROCUREMENT","METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER","METHOD_OF_SAMPLE_PROCUREMENT","MUTATION_COUNT","MUTATION_STATUS","MUTATION_TYPE","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","NUMBER_OF_LYMPHNODES_POSITIVE_BY_IHC","OCT_EMBEDDED","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_METHOD_OF_SAMPLE_PROCUREMENT","OTHER_PATIENT_ID","OTHER_SAMPLE_ID","PATHOLOGY_REPORT_FILE_NAME","PATHOLOGY_REPORT_UUID","PERFORMANCE_STATUS_TIMING","PHARMACEUTICAL_TX_ADJUVANT","POS_LYMPH_NODE_LOCATION","PRIMARY_SITE_OTHER","PRIMARY_SITE_PATIENT","PROJECT_CODE","PROSPECTIVE_COLLECTION","PULMONARY_FUNCTION_TEST_INDICATOR","RACE","RADIATION_TREATMENT_ADJUVANT","RESIDUAL_TUMOR","RETROSPECTIVE_COLLECTION","SAMPLE_COUNT","SAMPLE_INITIAL_WEIGHT","SAMPLE_TYPE","SAMPLE_TYPE_ID","SEX","SHORTEST_DIMENSION","SMOKING_PACK_YEARS","SMOKING_YEAR_STARTED","SMOKING_YEAR_STOPPED","SOMATIC_STATUS","SPECIMEN_CURRENT_WEIGHT","SPECIMEN_FREEZING_METHOD","SPECIMEN_SECOND_LONGEST_DIMENSION","STAGE_OTHER","TARGETED_MOLECULAR_THERAPY","TIME_BETWEEN_CLAMPING_AND_FREEZING","TIME_BETWEEN_EXCISION_AND_FREEZING","TISSUE_SOURCE_SITE","TMB_NONSYNONYMOUS","TOBACCO_SMOKING_HISTORY_INDICATOR","TREATMENT_OUTCOME_FIRST_COURSE","TUMOR_SITE","TUMOR_STATUS","VIAL_NUMBER"],"molecularProfileIds":["luad_tcga_gistic","luad_tcga_linear_CNA","luad_tcga_methylation_hm27","luad_tcga_methylation_hm450","luad_tcga_mrna","luad_tcga_mrna_median_Zscores","luad_tcga_mrna_median_all_sample_Zscores","luad_tcga_mutations","luad_tcga_rna_seq_v2_mrna","luad_tcga_rna_seq_v2_mrna_median_Zscores","luad_tcga_rna_seq_v2_mrna_median_all_sample_Zscores","luad_tcga_rppa","luad_tcga_rppa_Zscores"]}},{"studyId":"luad_tcga_gdc","name":"Lung Adenocarcinoma (TCGA, GDC)","sampleCount":587,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=luad_tcga_gdc","metadata":{"clinicalAttributeIds":["AGE","AJCC_STAGING_EDITION","BIOPSY_SITE","CANCER_TYPE","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_DEATH","DFS_MONTHS","DFS_STATUS","DISEASE_TYPE","ETHNICITY","FRACTION_GENOME_ALTERED","ICD_10","IS_FFPE","MORPHOLOGY","MUTATION_COUNT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","OTHER_SAMPLE_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_STAGE","PATH_T_STAGE","PRIMARY_DIAGNOSIS","PRIMARY_SITE_PATIENT","PRIOR_MALIGNANCY","PRIOR_TREATMENT","PROJECT_ID","PROJECT_NAME","PROJECT_STATE","RACE","SAMPLE_COUNT","SAMPLE_TYPE","SAMPLE_TYPE_ID","SEX","SMOKER_YEARS","SMOKING_PACK_YEARS","VITAL_STATUS","YEAR_OF_DIAGNOSIS"],"molecularProfileIds":["luad_tcga_gdc_cna","luad_tcga_gdc_mrna_seq_fpkm","luad_tcga_gdc_mrna_seq_fpkm_Zscores","luad_tcga_gdc_mrna_seq_read_counts_Zscores","luad_tcga_gdc_mrna_seq_tpm","luad_tcga_gdc_mrna_seq_tpm_Zscores","luad_tcga_gdc_mutations","luad_tcga_gdc_rna_seq_mrna"]}},{"studyId":"luad_tcga_pan_can_atlas_2018","name":"Lung Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":566,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=luad_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["luad_tcga_pan_can_atlas_2018_armlevel_cna","luad_tcga_pan_can_atlas_2018_genetic_ancestry","luad_tcga_pan_can_atlas_2018_gistic","luad_tcga_pan_can_atlas_2018_log2CNA","luad_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","luad_tcga_pan_can_atlas_2018_mutations","luad_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","luad_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","luad_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","luad_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","luad_tcga_pan_can_atlas_2018_rppa","luad_tcga_pan_can_atlas_2018_rppa_Zscores","luad_tcga_pan_can_atlas_2018_structural_variants"]}},{"studyId":"luad_tcga_pub","name":"Lung Adenocarcinoma (TCGA, Nature 2014)","sampleCount":459,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=luad_tcga_pub","metadata":{"clinicalAttributeIds":["AGE","CANCER_TYPE","CANCER_TYPE_DETAILED","DFS_MONTHS","DFS_STATUS","DISTANT_METASTASIS_PATHOLOGIC_SPREAD","FRACTION_GENOME_ALTERED","HISTOLOGICAL_SUBTYPE","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","MUTATION_COUNT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","PRETREATMENT_HISTORY","PRIMARY_TUMOR_PATHOLOGIC_SPREAD","PRIOR_DIAGNOSIS","RESIDUAL_TUMOR","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","TMB_NONSYNONYMOUS","TOBACCO_SMOKING_HISTORY_INDICATOR","TUMOR_STAGE_2009"],"molecularProfileIds":["luad_tcga_pub_gistic","luad_tcga_pub_linear_CNA","luad_tcga_pub_methylation_hm27","luad_tcga_pub_methylation_hm450","luad_tcga_pub_mrna","luad_tcga_pub_mrna_median_Zscores","luad_tcga_pub_mrna_median_all_sample_Zscores","luad_tcga_pub_mutations","luad_tcga_pub_rna_seq_v2_mrna","luad_tcga_pub_rna_seq_v2_mrna_median_Zscores","luad_tcga_pub_rna_seq_v2_mrna_median_all_sample_Zscores","luad_tcga_pub_rppa","luad_tcga_pub_rppa_Zscores","luad_tcga_pub_structural_variants"]}}]}}
```


Perfect! I found several lung adenocarcinoma studies. For the most comprehensive and up-to-date analysis, I recommend using the **TCGA PanCancer Atlas 2018** dataset (566 samples), which has excellent survival data and molecular profiling.

Now let me generate the direct link to view EGFR alterations with survival analysis:



Calling `navigate_to_resultsview_page` with args:
```json
{
  "studyIds": [
    "luad_tcga_pan_can_atlas_2018"
  ],
  "genes": [
    "EGFR"
  ],
  "tab": "survival"
}
```



Result from `navigate_to_resultsview_page`:
```json
{"success":true,"message":"Navigating to https://deploy-preview-5312--cbioportalfrontend.netlify.app/results/survival?cancer_study_list=luad_tcga_pan_can_atlas_2018&gene_list=EGFR&case_set_id=luad_tcga_pan_can_atlas_2018_all","url":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/results/survival?cancer_study_list=luad_tcga_pan_can_atlas_2018&gene_list=EGFR&case_set_id=luad_tcga_pan_can_atlas_2018_all","data":{"studyIds":["luad_tcga_pan_can_atlas_2018"],"studies":[{"studyId":"luad_tcga_pan_can_atlas_2018","name":"Lung Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":566}],"genes":["EGFR"],"caseSetId":"luad_tcga_pan_can_atlas_2018_all","molecularProfiles":["luad_tcga_pan_can_atlas_2018_mutations"]}}
```


Excellent! Here's your direct link to analyze survival differences for EGFR alterations in lung adenocarcinoma:

**ðŸ”— [View EGFR Survival Analysis in TCGA Lung Adenocarcinoma (PanCancer Atlas)](https://deploy-preview-5312--cbioportalfrontend.netlify.app/results/survival?cancer_study_list=luad_tcga_pan_can_atlas_2018&gene_list=EGFR&case_set_id=luad_tcga_pan_can_atlas_2018_all)**

---

## What You'll See:

This link takes you directly to the **Survival tab** for EGFR in the TCGA Lung Adenocarcinoma PanCancer Atlas (566 samples). The page will automatically:

1. **Separate patients into groups** based on EGFR alteration status:
   - EGFR-mutated patients
   - EGFR-amplified patients (CNA gain/amplification)
   - EGFR wild-type patients (no alterations)

2. **Display Kaplan-Meier survival curves** comparing these groups for:
   - Overall Survival (OS)
   - Disease-Free Survival (DFS)
   - Disease-Specific Survival (DSS)
   - Progression-Free Survival (PFS)

3. **Provide statistical analysis** including:
   - Log-rank test p-values
   - Median survival times for each group
   - Number of patients in each group

---

## How to Use the Page:

- **Switch survival types:** Use the dropdown menu to toggle between OS, DFS, DSS, and PFS
- **View detailed statistics:** Hover over the curves to see survival percentages at specific time points
- **Customize grouping:** You can further refine the alteration types (e.g., separate mutations by type, or distinguish amplification from gain)

This analysis will show you whether EGFR alterations are associated with better or worse survival outcomes in lung adenocarcinoma patients.

---

## Model Information
- **model**: us.anthropic.claude-sonnet-4-5-20250929-v1:0
- **temperature**: 0.0
- **max_output_tokens**: 1024
- **thinking_enabled**: False
- **thinking_budget_tokens**: 1024
- **response_time_seconds**: 23.853713877033442
- **agent_type**: mcp-navigator-agent

### Usage
- **input_tokens**: 71054
- **output_tokens**: 831
- **total_tokens**: 71885
- **cache_creation_input_tokens**: 0
- **cache_read_input_tokens**: 0

---

*Generated on 2026-02-05 01:45:13*